Autonomix Medical (NASDAQ:AMIX) Given New $2.00 Price Target at Maxim Group

Autonomix Medical (NASDAQ:AMIX) had its price target decreased by Maxim Group from $5.00 to $2.00 in a report released on Tuesday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Autonomix Medical in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $2.00.

Autonomix Medical Stock Performance

Shares of NASDAQ:AMIX opened at $0.37 on Tuesday. Autonomix Medical has a 1 year low of $0.34 and a 1 year high of $3.09. The stock has a market capitalization of $2.53 million, a P/E ratio of -0.10 and a beta of -2.58. The stock has a 50-day simple moving average of $0.51 and a 200-day simple moving average of $0.87.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings results on Wednesday, February 11th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.10. Analysts predict that Autonomix Medical will post -10 earnings per share for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.